drugset / Trial / NCT04225156
A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
Timeline
- Start
- 2020-06-02
- Primary completion
- 2026-03-11
- Completion
- 2026-03-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efgartigimod Alfa | Protein / enzyme biologic | 10 mg/kg | Intravenous |